Conclusions: Long-term use of oral NAC is associated with a higher risk of knee OA.

The use of oral NAC was associated with nearly four-fold increased the risk of knee OA in the young age group.

These findings show that low-dose oral NAC does not protect patients with head and neck cancer from cisplatin-induced toxicities and oxidative stress.